Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epcoritamab + R-CHOP in Newly Diagnosed Aggressive Non-Hodgkin Lymphoma
NCT07588698Phase 2Not yet recruiting
- Sponsor
- Carrie Ho
- Start
- Nov 2026
- Primary completion
- Aug 2028
- Countries
- 1
01
Overview
A Phase 2 trial of epcoritamab in diffuse large B-cell lymphoma (DLBCL), non-Hodgkin lymphoma (NHL), sponsored by Carrie Ho. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
epcoritamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT07588698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07588698.